FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person* STIGALL L. JEREMY				2. Issuer Name and Ticker or Trading Symbol ClearPoint Neuro, Inc. [CLPT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)Director 10% Owner							
(Last) (First) (Middle) C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100				3. Date of Earliest Transaction (Month/Day/Year) 07/06/2022						X_Offic	X Officer (give title below) Other (specify below) GM, Biologics & Drug Delivery							
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person								
SOLANA BEACH, CA 92075 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
(Instr. 3) Da		2. Transaction Date (Month/Day/Year)			(Instr. 8)		4. Securities Acquir (A) or Disposed of ((Instr. 3, 4 and 5)			equired	5. Amou Beneficia Reported	nt of Securities ally Owned Following I Transaction(s)		6. Ownershi Form:	of Be	7. Nature of Indirect Beneficial		
				(Month/Day/Year		ear)		ode	V	Amour	(A) or (D)	Price	(Instr. 3 a	and 4)		Direct (D) or Indirec (I) (Instr. 4)	Indirect (Instr	
Common Stock 0		07/06/2022				F			1,685 (1)	D	\$ 13.87	7 41,526	41,526		D			
								quire	the f	orm di isposed	splays a	a curi enefici	ently valid	uired to res I OMB con				
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/V	3A. Deemed Execution Da any	4. Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ai Ui Se	Title and mount of nderlying courities nstr. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form of Deriva Securi Direct or Indi	of tive ty: (D) rect	Beneficia Ownersh (Instr. 4)		
					Code	V	(A)	(D)	Date Exe	e rcisable	Expirati Date	ion Ti	Amount or Number of Shares					
Repor	ting O	wners																

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
STIGALL L. JEREMY C/O CLEARPOINT NEURO, INC. 120 S. SIERRA AVE., SUITE 100 SOLANA BEACH, CA 92075			GM, Biologics & Drug Delivery					

Signatures

/s/ Richard F. Mattern by Power of Attorney for Jeremy L. Stigall	07/08/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.